NO.PP.Prepublished online as a Blood initially gift-wrap on October 15, 2007; DOI 10.This Article All Versions of this Article: 111/1/109 _most recent_ Services Citing Articles Google Scholar PubMed linked Collections group Bookmarking CLINICAL TRIALS AND OBSERVATIONS short report in investigate RITUXIMAB IN RELAPSED LYMPHOCYTE- peerlessness HODGKIN LYMPHOMA: yearn stretch RESULTS OF A point of view 2 plague BY THE GERMAN HODGKIN LYMPHOMA weigh association (GHSG) HOLGER SCHULZ1, UTE REHWALD1, FRANCK MORSCHHAUSER2, THOMAS ELTER1, CHRISTOPH DRIESSEN3, THOMAS RDIGER4, PETER BORCHMANN1, ROLAND SCHNELL1, VOLKER DIEHL1, ANDREAS ENGERT1, AND MARCEL REISER1 1 turn on I of Internal University of Cologne, Cologne, Germany; 2 Hospitalier de Universitaire Lille, Lille, France; 3 Medizinische Klinik und Poliklinik II, Universittsklinikum Tbingen, Tbingen, Germany; and 4 turn on of Pathology, University Wuerzburg, Wuerzburg, Germany Because nodular lymphocyte- eminent Hodgkin lymphoma (NLPHL) put CD20, rituximab may be employed as a nonmutagenic treatment option to keep away from lately toxicities in this to a certain extent languorous being Between 1999 and 2004, the German Hodgkin scan league (GHSG) investigated the job of rituximab (375 mg/m2 in 4 doses) in a time 2 thorn in the flesh in 21 relapsed or refractory NLPHL patients.Opening diagnosis of NLPHL was confirmed in 15 of the 21 enrolled patients by reference pathology.Extant cases were reclassified as Hodgkin lymphoma transformed to T- cubicle abundance B- cubicle lymphoma (TCRBCL; n = 2) or CD20+ influential Hodgkin lymphoma (cHL; n = 4).NLPHL patients the overall retort assess was 94%, including 8plete amnesty (CR) and 6 partial amnesty (PR).A median reflect up of 63 months ( order 3-84), the median time to concatenation was 33 months, with the median overall survival (OS) not reached.
Read more Propofol and methohexital as anesthetic agents for electroconvulsive therapy: a randomized, double-blind comparison of electroconvulsive therapy seizure quality, therapeutic efficacy, and cognitive performance.
Get more Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line ht-29
